Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Clinical evidence

CLXS196X2101

51 evidence topics · 3 sources

Objective
Location and study date
Registry protocol number and study dates
Study characteristicQuoted record
Other study ID number“CLXS196X2101”
Study start (actual)“2016-02-01”
Primary completion (actual)“2022-01-07”
Study completion (actual)“2022-01-07”
Study design
Registry design and status: nonrandomized, open-label, single group; combination part terminated
Study characteristicQuoted record
Primary purpose“Treatment”
Allocation“Non-Randomized”
Interventional model“Single Group Assignment”
Masking“None (Open Label)”
Eligibility criteria
Treatment
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics by schedule and at the recommended dose for expansion
CharacteristicAll QD, n = 38All BID, n = 30300 mg BID (RDE), n = 18All patients, N = 68
Median age, years (range)“55 (26–76)”View highlighted excerpt for this quote“57 (33–78)”View highlighted excerpt for this quote“56.5 (38–76)”View highlighted excerpt for this quote“56 (26–78)”View highlighted excerpt for this quote
Male, n (%)“22 (57.9)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“7 (38.9)”View highlighted excerpt for this quote“36 (52.9)”View highlighted excerpt for this quote
Female, n (%)“16 (42.1)”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“11 (61.1)”View highlighted excerpt for this quote“32 (47.1)”View highlighted excerpt for this quote
ECOG performance status 0, n (%)“37 (97.4)”View highlighted excerpt for this quote“25 (83.3)”View highlighted excerpt for this quote“14 (77.8)”View highlighted excerpt for this quote“62 (91.2)”View highlighted excerpt for this quote
ECOG performance status 1, n (%)“1 (2.6)”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“6 (8.8)”View highlighted excerpt for this quote
Lactate dehydrogenase above ULN, n (%)“23 (60.5)”View highlighted excerpt for this quote“15 (50.0)”View highlighted excerpt for this quote“8 (44.4)”View highlighted excerpt for this quote“38 (55.9)”View highlighted excerpt for this quote
No prior systemic therapy, n (%)“3 (7.9)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“6 (33.3)”View highlighted excerpt for this quote“9 (13.2)”View highlighted excerpt for this quote
One prior systemic therapy, n (%)“19 (50.0)”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“9 (50.0)”View highlighted excerpt for this quote“37 (54.4)”View highlighted excerpt for this quote
Two prior systemic therapies, n (%)“12 (31.6)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“14 (20.6)”View highlighted excerpt for this quote
More than two prior systemic therapies, n (%)“4 (10.5)”View highlighted excerpt for this quote“4 (13.3)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“8 (11.8)”View highlighted excerpt for this quote
Any prior immunotherapeutic agent, n (%)“22 (57.9)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“36 (52.9)”View highlighted excerpt for this quote
Prior pembrolizumab, n (%)“11 (28.9)”View highlighted excerpt for this quote“10 (33.3)”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“21 (30.9)”View highlighted excerpt for this quote
Liver-only metastases, n (%)“13 (34.2)”View highlighted excerpt for this quote“14 (46.7)”View highlighted excerpt for this quote“9 (50.0)”View highlighted excerpt for this quote“27 (39.7)”View highlighted excerpt for this quote
Liver and other metastases, n (%)“20 (52.6)”View highlighted excerpt for this quote“13 (43.3)”View highlighted excerpt for this quote“7 (38.9)”View highlighted excerpt for this quote“33 (48.5)”View highlighted excerpt for this quote
Maximum target lesion diameter, median mm (range)“39 (11–126)”View highlighted excerpt for this quote“35.5 (11–201)”View highlighted excerpt for this quote“40 (11–201)”View highlighted excerpt for this quote“36 (11–201)”View highlighted excerpt for this quote
Demographics, metastatic sites, and prior therapy

“The median age was 56.0 years, 36 (52.9%) were male, and most (n = 62; 91.2%) had a performance status of 0. The majority of patients (n = 60; 88.2%) had liver metastases, 27 of whom (14 in the BID schedule and 13 in the QD schedule) had only liver metastases and no other sites of disease at study entry.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Other reported metastatic sites with an incidence of at least 10% included lung (n = 18, 26.5%), bone (n = 13, 19.1%), lymph node (n = 8, 11.8%) and skin (n = 7, 10.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 59 patients (86.8%) had received prior systemic therapy; the majority having received either one (n = 37, 54.4%) or two prior regimens (n = 14, 20.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The majority of patients (n = 31, 45.6%) had PD as the best overall response (BOR) to their last prior therapy and in these patients, the median time from initiation to discontinuation of last prior therapy was 63 days (range: 14–515).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“No patients had received prior tebentafusp.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Efficacy results
Best overall response and progression-free survival by schedule and at the recommended dose for expansion
OutcomeAll QD, n = 38All BID, n = 30300 mg BID (RDE), n = 18All patients, N = 68
Complete response, n (%)“0”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Partial response, n (%)“2 (5.3)”View highlighted excerpt for this quote“3 (10.0)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“5 (7.4)”View highlighted excerpt for this quote
Stable disease, n (%)“27 (71.1)”View highlighted excerpt for this quote“18 (60.0)”View highlighted excerpt for this quote“12 (66.7)”View highlighted excerpt for this quote“45 (66.2)”View highlighted excerpt for this quote
Progressive disease, n (%)“9 (23.7)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“15 (22.1)”View highlighted excerpt for this quote
Objective response rate, 95% CI“[0.6–17.7]”View highlighted excerpt for this quote“[3.8–30.7]”View highlighted excerpt for this quote“[1.4–34.7]”View highlighted excerpt for this quote“[3.3–18.2]”View highlighted excerpt for this quote
Disease control rate, n (%)“29 (76.3)”View highlighted excerpt for this quote“22 (73.3)”View highlighted excerpt for this quote“14 (77.8)”View highlighted excerpt for this quote“51 (75.0)”View highlighted excerpt for this quote
Disease control rate, 95% CI“[59.8–88.6]”View highlighted excerpt for this quote“[54.1–87.7]”View highlighted excerpt for this quote“[52.4–93.6]”View highlighted excerpt for this quote“[63–84.7]”View highlighted excerpt for this quote
Median progression-free survival, months (95% CI)“3.5 (3.5–5.4)”View highlighted excerpt for this quote“4.1 (3.5–7.2)”View highlighted excerpt for this quote“3.7 (2.1–5.4)”View highlighted excerpt for this quote“3.6 (3.5–5.4)”View highlighted excerpt for this quote
Progression-free survival rate at 4 months, % (95% CI)“36.8 (22.0–51.8)”View highlighted excerpt for this quote“50.0 (31.3–66.1)”View highlighted excerpt for this quote“44.4 (21.6–65.1)”View highlighted excerpt for this quote“42.6 (30.8–54.0)”View highlighted excerpt for this quote
Progression-free survival rate at 6 months, % (95% CI)“26.3 (13.7–40.8)”View highlighted excerpt for this quote“33.3 (17.5–50.0)”View highlighted excerpt for this quote“27.8 (10.1–48.9)”View highlighted excerpt for this quote“29.4 (19.1–29.2)”View highlighted excerpt for this quote
Progression-free survival rate at 12 months, % (95% CI)“0.0 (NE–NE)”View highlighted excerpt for this quote“26.7 (12.6–43.0)”View highlighted excerpt for this quote“22.2 (6.9–42.9)”View highlighted excerpt for this quote“11.8 (5.5–20.6)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Dose-limiting toxicities and declaration of the maximum tolerated doses and recommended dose for expansion
Adverse events suspected to be related to LXS196 by schedule and at the recommended dose for expansion
Preferred termAll QD, n = 38, all gradesAll QD, grade 3 or higherAll BID, n = 30, all gradesAll BID, grade 3 or higher300 mg BID (RDE), n = 18, all grades300 mg BID (RDE), grade 3 or higherAll patients, N = 68, all gradesAll patients, grade 3 or higher
Participants with at least 1 adverse event, n (%)“35 (92.1)”View highlighted excerpt for this quote“11 (28.9)”View highlighted excerpt for this quote“28 (93.3)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“17 (94.4)”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“63 (92.6)”View highlighted excerpt for this quote“17 (25.0)”View highlighted excerpt for this quote
Nausea, n (%)“26 (68.4)”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“19 (63.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“14 (77.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“45 (66.2)”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Diarrhoea, n (%)“15 (39.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“16 (53.3)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“11 (61.1)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“31 (45.6)”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Vomiting, n (%)“12 (31.6)”View highlighted excerpt for this quote“1 (2.6)”View highlighted excerpt for this quote“9 (30.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (38.9)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“21 (30.9)”View highlighted excerpt for this quote“1 (1.5)”View highlighted excerpt for this quote
Alanine aminotransferase increased, n (%)“7 (18.4)”View highlighted excerpt for this quote“2 (5.3)”View highlighted excerpt for this quote“8 (26.7)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“5 (27.8)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“15 (22.1)”View highlighted excerpt for this quote“4 (5.9)”View highlighted excerpt for this quote
Hypotension, n (%)“8 (21.1)”View highlighted excerpt for this quote“5 (13.2)”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“1 (3.3)”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“15 (22.1)”View highlighted excerpt for this quote“6 (8.8)”View highlighted excerpt for this quote
Fatigue, n (%)“10 (26.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (13.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“14 (20.6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Asthenia, n (%)“6 (15.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (23.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“13 (19.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Aspartate aminotransferase increased, n (%)“5 (13.2)”View highlighted excerpt for this quote“2 (5.3)”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“2 (6.7)”View highlighted excerpt for this quote“3 (16.7)”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“11 (16.2)”View highlighted excerpt for this quote“4 (5.9)”View highlighted excerpt for this quote
Dry skin, n (%)“2 (5.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“6 (20.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“8 (11.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Rash, n (%)“3 (7.9)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“4 (22.2)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“8 (11.8)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Blood creatinine increased, n (%)“2 (5.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“5 (16.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (11.1)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (10.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Constipation, n (%)“4 (10.5)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“3 (10.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (5.6)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“7 (10.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Adverse events regardless of relationship, serious adverse events, and tolerability of the two schedules

“The majority of patients (n = 66; 97.1%) experienced an AE regardless of study drug relationship during the study; 29 (42.6%) of these patients experienced AEs of grade 3/4 (Supplementary Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most frequent AEs with LXS196 (all grades, all doses, both schedules) were nausea (n = 48; 70.6%), diarrhoea (n = 37; 54.4%), vomiting (n = 26; 38.2%), fatigue (n = 19; 27.9%), increased alanine aminotransferase (ALT, n = 18; 26.5%), constipation (n = 17; 25%), asthenia (n = 15; 22.1%) and hypotension (n = 15; 22.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most frequent AEs of grade ≥3, regardless of study drug relationship, were hypotension (n = 6; 8.8%), increased aspartate aminotransferase (AST, n = 5; 7.4%) and increased ALT (n = 4; 5.9%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Serious AEs (SAEs) were observed in 14 (20.6%) patients, and all were grade 3/4; the most frequent were hypotension (n = 6; 8.8%) and pneumonia (n = 3; 4.4%) (Table 2C). BID appeared to be better tolerated than QD dosing, with fewer treatment-related grade 3/4 AEs and treatment-related SAEs. Grade 3/4 hypotension was more common in the QD versus the BID groups (13.2% versus 3.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Study limitations
Summary

CLXS196X2101 is a nonrandomized, open-label, single-group phase 1 study of LXS196 (darovasertib) as a single agent, without crizotinib. No hypothesis testing was planned and no formal sample size calculation was made; data are presented descriptively. Of the 68 participants, 59 (86.8%) had received prior systemic therapy, and none had received prior tebentafusp. Participants were treated across once-daily doses of 100 to 1000 mg (n = 38) and twice-daily doses of 200 to 400 mg (n = 30), and 18 were evaluable at the recommended dose for expansion of 300 mg twice daily. Tumour response was assessed locally per RECIST v1.1. The ORR denominator differs between the text (6 of 66 evaluable participants, 9.1%) and the results table, which includes 2 participants without post-baseline assessment in a denominator of 68; the 95% CI of the 6-month PFS rate in all participants is 19.1 to 40.4 in the text and 19.1 to 29.2 in the table. Pharmacodynamic analysis was not performed on tumour samples from the twice-daily schedule, the authors note that the C1D15 biopsy timepoint might be too late to observe transient changes, and the sequencing panel did not include CYSLTR2 and PLCB4. The combination part with HDM201 was terminated early for business reasons. No quality-of-life or patient-reported outcome results were reported; the registry outcomes cover dose-limiting toxicities, adverse events, dose modifications, ORR, PFS, and pharmacodynamics.